NCT06835569
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06835569
Title A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Alterome Therapeutics, Inc.
Indications
Advanced Solid Tumor
Therapies
ALTA3263 + Pembrolizumab
ALTA3263 + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin
ALTA3263
ALTA3263 + Midazolam
ALTA3263 + Cetuximab
ALTA3263 + Cetuximab + Gemcitabine + Nab-paclitaxel
ALTA3263 + Cisplatin + Pembrolizumab + Pemetrexed Disodium
ALTA3263 + Carboplatin + Pembrolizumab + Pemetrexed Disodium
ALTA3263 + Gemcitabine + Nab-paclitaxel
ALTA3263 + Fluorouracil + Leucovorin + Oxaliplatin
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Research Site RECRUITING Orlando Florida 32827 United States Details
Research Site RECRUITING Boston Massachusetts 02114 United States Details
Research Site RECRUITING Boston Massachusetts 02115 United States Details
Research Site RECRUITING St Louis Missouri 63110 United States Details
Research Site RECRUITING New York New York 10016 United States Details
Research Site RECRUITING New York New York 10032 United States Details
Research Site RECRUITING Durham North Carolina 27710 United States Details
Research Site RECRUITING Nashville Tennessee 37203 United States Details
Research Site RECRUITING Houston Texas 77030 United States Details
Research Site #2 RECRUITING San Antonio Texas 78229 United States Details
Research Site RECRUITING San Antonio Texas 78229 United States Details
Research Site RECRUITING Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field